



Contact:

Dr. Misha Plam
President & CEO
T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

Thomas “Tom” Keuer joins the Business Advisory Board of AmideBio, LLC

BOULDER, CO, April 4, 2011 – AmideBio, LLC, a privately held biopharmaceutical company which has developed novel manufacturing processes for peptides and proteins, announced today that Thomas A. Keuer, EVP of Arca biopharma, Inc., a Broomfield, Colorado-based biopharmaceutical company, has joined its Business Advisory Board.

Mr. Keuer brings over 30 years of technical expertise in the biotechnology and pharmaceutical industries, including leadership positions with Arca biopharma, Insmmed, Baxter International, Somatogen and Monsanto. In his current position with ARCA, Tom has overall responsibility for the company’s technical development programs in the chemistry, manufacturing and controls (CMC) area, and also serves as the head of project management. Prior to ARCA, he was Senior Vice President of Insmmed Therapeutic Proteins, with responsibility for all process development and manufacturing programs at the company, including leadership of the GMP manufacturing site in Boulder, CO. Prior to Insmmed, Tom was Vice President of Engineering for Baxter International’s Bioscience Division, a position that involved global responsibility for all capital projects related to manufacturing of biotechnology products. Tom also served as Vice President of Manufacturing for Somatogen, Inc, a Boulder-based biotechnology company. He received his Masters of Science in Biochemical Engineering from Rice University as a Monsanto-sponsored delegate.

“We are very pleased to have Tom Keuer join our Business Advisory Board,” said Dr. Misha Plam, AmideBio President and CEO. “Tom brings to the Company extensive knowledge of the biotech and pharmaceutical industries and specifically, large-scale manufacturing of peptides and proteins under GMP compliance. His insights and experiences will prove vital to the Company as AmideBio moves to our next stage of growth and development in the Biosimilars market.”

“I’m very excited about the prospects for AmideBio,” said Tom Keuer, “The Company’s core processing technologies offer significant, potential advantages across a broad spectrum of product opportunities, including the large-scale manufacturing of Biosimilars and Biotherapeutics.”

About AmideBio:

AmideBio, based in Boulder, CO, is a biotechnology company founded on a unique process for the production of peptides and proteins, especially those that have been historically difficult to manufacture or produce in large quantities. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process is providing the research community with some of the most pure peptide-derived

products available to date, including amyloid-beta, an important protein believed to be involved with Alzheimer disease. The Company's platform offers an economical and environmentally sustainable process for large-scale production of biosimilars, with the aim of providing patients with lower-cost medications. AmideBio's technology is the foundation for internal drug discovery and development against diseases such as Diabetes and Alzheimer's, where our BioPure™ materials have allowed for the discovery of novel targets as well as potential improvements in existing therapeutics.

- ENDS